CanSino Biologics Inc.’s experimental coronavirus vaccine has an efficacy rate of 65.7% at preventing symptomatic cases based on an analysis from late-stage trials, adding a one-shot candidate to the world’s growing arsenal against Covid-19.
The inoculation co-developed by the Chinese military and the Tianjin-based biotech company proved effective against symptomatic Covid-19, based on a multi-country analysis first posted on Twitter by Faisal Sultan, Pakistan’s health adviser, on Monday. CanSino later forwarded Sultan’s announcement in a statement. The final stage trial included 30,000 participants and was also 90.98% effective in preventing severe disease, Sultan said.
